NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-TR-19-015 from the NIH Guide for Grants and Contracts
Notice NOT-EB-19-002 from the NIH Guide for Grants and Contracts
Notice NOT-CA-19-019 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-MH-20-210 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites an application to continue a Connectome Coordination Facility.The competition is limited to the R24 awardee of RFA-MH-15-750.The goal of this award is to (1) maintain a central data repository for Human Connectome data; (2) provide a helpdesk service to answer questions from investigators who are trying to collect data that are compatible with the existing Human Connectome data; and (3) to serve, in a limited capacity, to check quality control and harmonize data from existing Connectome awardees.
Funding Opportunity RFA-HL-20-012 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The EIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The EIA will support the research program of NHLBI-funded investigators for up to seven years. The EIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the EIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).
Funding Opportunity RFA-HL-20-011 from the NIH Guide for Grants and Contracts. The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PD/PIs) who are currently PD/PIs on at least two NHLBI R01-equivalent awards and whose outstanding record of research demonstrates their ability to make major contributions to heart, lung, blood and sleep (HLBS) research. The OIA is intended to support a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. The OIA will support the research program of NHLBI-funded investigators for up to seven years. The OIA will provide investigators increased freedom to conduct research that breaks new ground or extends previous discoveries in new directions. It will also allow PD/PIs to take greater risks and to pursue research that requires a longer timeframe. Research supported by the OIA must be within the scope of the NHLBI mission (http://www.nhlbi.nih.gov/about/org/mission).
Notice NOT-DC-19-005 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-065 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-066 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-059 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-19-169 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.
Funding Opportunity PAR-19-168 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications investigating the biology and underlying mechanisms of bladder cancer. Bladder cancer is a significant health problem both in the United States and globally. Because of the high incidence and frequent tumor recurrence, bladder cancer exacts an outsized medical burden. While recent progress has been made in the molecular profiling of bladder cancers and identification of mutated genes, relatively little is known regarding the molecular mechanisms driving initiation, progression, and malignancy of bladder cancer. Furthermore, our understanding of biological processes of the normal bladder at the molecular, cell and organ levels is limited. Fundamental knowledge of how molecular and cellular functions of the bladder are altered in cancer will aid our understanding of bladder cancer biology and interventions. Applications that involve multidisciplinary teams and use clinical specimens or investigate both normal and cancer processes are encouraged.
Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)
Funding Opportunity RFA-CA-19-032 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to advance our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS) through research directed at addressing one of several proposed "Provocative Questions" (PQs). These PQs are not intended to represent the full range of NCI's priorities in HIV/AIDS-related cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems and paradoxes in key areas of AIDS-related cancer research that are deemed important but have not received sufficient attention. Provocative Questions in Cancer with an Underlying HIV Infection involves a set of 6 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.
Funding Opportunity RFA-AI-19-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV Vaccines Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV Vaccines Clinical Trials Network.
Funding Opportunity RFA-AI-19-001 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for HIV/AIDS Clinical Trials Networks Laboratory Centers (LCs). Each LC will be responsible for providing a framework for laboratory leadership, structure and activities that contribute to the development and execution of the laboratory elements of NIAID HIV/AIDS Clinical Trials Networks research agendas.
Funding Opportunity RFA-AI-19-005 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV Prevention Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV Prevention Clinical Trials Network.
Funding Opportunity RFA-AI-19-004 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV/AIDS Maternal, Adolescent and Pediatric Therapeutics Clinical Trials Network.
Funding Opportunity RFA-AI-19-003 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a HIV/AIDS Adult Therapeutics Clinical Trials Network Leadership and Operations Center (LOC). The LOC will be responsible for the overall administrative and scientific leadership for the HIV/AIDS Adult Therapeutics Clinical Trials Network.
Funding Opportunity RFA-AI-19-002 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for HIV/AIDS Clinical Trials Networks Statistical and Data Management Centers (SDMCs). The SDMCs will be responsible for the statistical and data management leadership and coordination critical to the NIAID HIV/AIDS Clinical Trials Networks.
Funding Opportunity PAR-19-170 from the NIH Guide for Grants and Contracts. This purpose of this FOA is to identify risk factors for dementia progression in PDD. Applicants must have access to well-characterized populations of PDD patients that have been followed longitudinally that they can continue to follow with clinical assessments and biospecimen collection until autopsy. Research should propose to identify clinical, pathological and/or biospecimen factors that predict which patients will develop cognitive impairment and/or dementia.